# STK40

## Overview
STK40, or serine/threonine kinase 40, is a gene that encodes a protein categorized as a pseudokinase, which is involved in a variety of cellular processes. Unlike typical kinases, pseudokinases lack catalytic activity but can still play crucial roles in signaling pathways by acting as scaffolds or regulators. The STK40 protein is primarily localized in the nucleus and is known to interact with several key proteins, including the E3 ubiquitin ligase COP1, influencing processes such as transcription regulation, cell cycle control, and protein degradation. It is particularly significant in pathways related to adipogenesis, mesoderm differentiation, and trophoblast cell function. The gene's expression and function have been linked to several diseases, including cancer and preeclampsia, highlighting its potential as a therapeutic target (Li2024STK40; Hu2019Stk40; Jacobsen2017The).

## Function
STK40 (serine/threonine kinase 40) is a pseudokinase involved in various cellular processes, including the regulation of transcription factors and cell cycle control. It predominantly localizes in the nucleus and interacts with the E3 ubiquitin ligase COP1, playing a role in the regulation of histone deacetylases (HDACs) (Jacobsen2017The). STK40 is implicated in the translational control of CCAAT/enhancer-binding proteins (C/EBPs), which are critical for adipogenesis. It represses the translation of C/EBP family members, affecting adipogenic differentiation by modulating the mTOR pathway (Yu2015Stk40).

In mesoderm differentiation, STK40 interacts with c-JUN, a component of the AP-1 transcription factor complex, promoting its degradation through the ubiquitin-proteasome system. This interaction is crucial for maintaining appropriate c-JUN levels, which are necessary for proper mesoderm development (Hu2019Stk40). STK40 also affects the WNT signaling pathway, influencing mesoderm differentiation by modulating c-JUN protein levels (Hu2019Stk40).

In trophoblast cells, STK40 inhibits cell fusion by mediating the ubiquitination and degradation of P57, a protein involved in cell cycle regulation. This activity affects cell cycle progression and protein degradation pathways, highlighting STK40's role in cellular processes related to cell viability and proliferation (Li2024STK40).

## Clinical Significance
Alterations in the expression or function of the STK40 gene have been implicated in various diseases and conditions. In triple-negative breast cancers (TNBC), STK40 is overexpressed in a subset of cases, and its depletion in breast cancer cells leads to apoptosis, suggesting its role in cell survival and potential as a therapeutic target (Maubant2018LRP5). In gastric cancer, STK40 is identified as a critical senescence-related gene, with higher expression levels in cancerous tissues compared to normal tissues. Knocking down STK40 impairs cancer cell proliferation and reduces reactive oxygen species accumulation, indicating its involvement in cancer progression and potential impact on therapeutic responses (Sun2023Construction).

STK40 also plays a role in preeclampsia (PE), a pregnancy-related condition. Its expression is significantly upregulated in the placentas of women with PE, where it inhibits trophoblast fusion by mediating the degradation of the P57 protein, contributing to impaired placental function (Li2024STK40). In psoriasis, STK40 is targeted by miR-31, leading to its repression and affecting inflammatory cytokine production, highlighting its involvement in inflammatory processes (Xu2013MicroRNA31). These findings underscore the clinical significance of STK40 in various pathological conditions.

## Interactions
STK40 (serine/threonine kinase 40) is involved in several protein interactions that influence cellular processes. It interacts with the E3 ubiquitin ligase COP1, facilitating the ubiquitination and degradation of specific proteins. This interaction is crucial for the regulation of proteins such as c-JUN and P57kip2. STK40 acts as an adaptor, recruiting substrates like c-JUN for degradation, which is essential for mesoderm differentiation and the modulation of WNT signaling pathways (Hu2019Stk40).

STK40 also interacts with P57kip2, a protein involved in cell cycle regulation. This interaction leads to the ubiquitination and degradation of P57kip2, mediated by COP1, which impacts trophoblast fusion and is linked to placental pathologies such as preeclampsia (Li2024STK40). The binding of STK40 to P57kip2 occurs at the CDK-binding and Cyclin-binding domains, highlighting its role in cell cycle control (Li2024STK40).

The interaction between STK40 and c-JUN is modulated by phosphorylation, with the C-terminal region of STK40 being necessary for this interaction. Phosphorylation at Ser-6 in the N-terminal region affects the binding affinity, suggesting a regulatory mechanism for c-JUN degradation (Hu2019Stk40).


## References


[1. (Hu2019Stk40) Jing Hu, Shuang Li, Xiaozhi Sun, Zhuoqing Fang, Lina Wang, Feng Xiao, Min Shao, Laixiang Ge, Fan Tang, Junjie Gu, Hongyao Yu, Yueshuai Guo, Xuejiang Guo, Bing Liao, and Ying Jin. Stk40 deletion elevates c-jun protein level and impairs mesoderm differentiation. Journal of Biological Chemistry, 294(25):9959–9972, June 2019. URL: http://dx.doi.org/10.1074/jbc.ra119.007840, doi:10.1074/jbc.ra119.007840. This article has 4 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra119.007840)

[2. (Sun2023Construction) Weijie Sun, Yihang Yuan, Jiaying Chen, Qun Bao, Mengsi Shang, Peng Sun, and Haixia Peng. Construction and validation of a novel senescence-related risk score can help predict the prognosis and tumor microenvironment of gastric cancer patients and determine that stk40 can affect the ros accumulation and proliferation ability of gastric cancer cells. Frontiers in Immunology, October 2023. URL: http://dx.doi.org/10.3389/fimmu.2023.1259231, doi:10.3389/fimmu.2023.1259231. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2023.1259231)

[3. (Xu2013MicroRNA31) Ning Xu, Florian Meisgen, Lynn M. Butler, Gangwen Han, Xiao-Jing Wang, Cecilia Söderberg-Nauclér, Mona Ståhle, Andor Pivarcsi, and Enikö Sonkoly. Microrna-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. The Journal of Immunology, 190(2):678–688, January 2013. URL: http://dx.doi.org/10.4049/jimmunol.1202695, doi:10.4049/jimmunol.1202695. This article has 163 citations.](https://doi.org/10.4049/jimmunol.1202695)

[4. (Li2024STK40) Xia Li, Li-Zhen Shao, Zhuo-Hang Li, Yong-Heng Wang, Qin-Yu Cai, Shun Wang, Hong Chen, Jie Sheng, Xin Luo, Xue-Mei Chen, Ying-Xiong Wang, Yu-Bin Ding, and Tai-Hang Liu. Stk40 inhibits trophoblast fusion by mediating cop1 ubiquitination to degrade p57kip2. Journal of Translational Medicine, September 2024. URL: http://dx.doi.org/10.1186/s12967-024-05360-y, doi:10.1186/s12967-024-05360-y. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12967-024-05360-y)

[5. (Jacobsen2017The) Annette V. Jacobsen and James M. Murphy. The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases. Biochemical Society Transactions, 45(3):665–681, June 2017. URL: http://dx.doi.org/10.1042/bst20160331, doi:10.1042/bst20160331. This article has 72 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst20160331)

[6. (Yu2015Stk40) Hongyao Yu, Ke He, Lina Wang, Jing Hu, Junjie Gu, Chenlin Zhou, Rui Lu, and Ying Jin. Stk40 represses adipogenesis through translational control of ccaat/enhancer-binding proteins. Journal of Cell Science, January 2015. URL: http://dx.doi.org/10.1242/jcs.170282, doi:10.1242/jcs.170282. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.170282)

[7. (Maubant2018LRP5) Sylvie Maubant, Tania Tahtouh, Amélie Brisson, Virginie Maire, Fariba Némati, Bruno Tesson, Mengliang Ye, Guillem Rigaill, Maïté Noizet, Aurélie Dumont, David Gentien, Bérengère Marty-Prouvost, Leanne de Koning, Sardar Faisal Mahmood, Didier Decaudin, Francisco Cruzalegui, Gordon C. Tucker, Sergio Roman-Roman, and Thierry Dubois. Lrp5 regulates the expression of stk40, a new potential target in triple-negative breast cancers. Oncotarget, 9(32):22586–22604, April 2018. URL: http://dx.doi.org/10.18632/oncotarget.25187, doi:10.18632/oncotarget.25187. This article has 22 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.25187)